WO1997022376A1 - Nebuliseur - Google Patents
Nebuliseur Download PDFInfo
- Publication number
- WO1997022376A1 WO1997022376A1 PCT/GB1996/003201 GB9603201W WO9722376A1 WO 1997022376 A1 WO1997022376 A1 WO 1997022376A1 GB 9603201 W GB9603201 W GB 9603201W WO 9722376 A1 WO9722376 A1 WO 9722376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gas
- nebuliser
- supply
- liquid
- nebulizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
Definitions
- Nebulizers are used to produce a liquid m fine droplet form in a gas flow, typically a liquid in the form of medication which is to be entrained in an air or oxygen gas flow and which is then breathed by a patient whereby the medication is supplied to the patient through the lungs.
- Nebulizers are becoming widely used in hospitals and other medical situations. Such as
- nebulizers have particular application in the delivery of drugs for the treatment of lung diseases.
- ⁇ e drug may be given as an inhaled drug aerosol, and this has many advantages over drugs which are taken systemically. It has become apparent that the size of the droplets plays an important role in how the drug is received by
- European Patent specification EP-A-573457 demonstrates a typical nebulizer and there is included in that specification details of the effect of droplet size on the delivery of the medicauon.
- the present invention provides a nebulizer comprising a pressure gas inlet, means for passing liquid medication to nebulising means associated with said pressure gas inlet
- the nebulizer may include a reservoir for said liquid medication, and the control means may include means to vary the size of the supply means so as to vary the amount of further gas passing through said further gas supply means.
- the control means may be in the form of a variable aperture, which may be provided by an aperture with a plate with a cooperating aperture therein, the plate being moveable.
- the control means may also include a one way valve.
- An advantage of the arrangement of the invention is that the quantity and relative constitution of the nebulized mixture may be changed by varying the control means to control the supply of further gas.
- Figure 1 is a axial section through a nebulizer according to the invention
- Figure 2 is a perspective view of the nebulizer of Figure 1 from the right
- Figure 3 is a view similar to Figure 2 of the nebulizer with the air controller in a second position
- Figure 4 is a view corresponding to Figures 2 and 3 of the nebulizer, with the air controller missing, showing the inlet air valve,
- Figure 5 is a pan view showing one line of ratchet teeth mounted on the nebul ⁇ zer( with air controller missing), and,
- Figure 6 is rear view of the air controller showing the teeth to engage the ratchet shown in Figure 5.
- FIG. 1 there is shown an axial section through a nebulizer (10).
- the section shown in Figure 1 comp ⁇ ses, on the left hand side of the Figure 1 , a first ve ⁇ ical section, and on the ⁇ ght hand side of the Figure a second ve ⁇ icaJ section at ⁇ ght angles to the first
- the nebulizer is manufactured of ⁇ gid moulded plastics mate ⁇ al.
- the nebulizer compnses a base section (1 1) which includes an inlet tube ( 12) for connection to a flexible plastic tube supplying pressurized gas, such as oxygen or air.
- the inlet tube (12) is sunounded by a threaded collar (13).
- Forming pan of the base section ( 1 1) but separately moulded is a second moulding ( 16) which includes; (a) a cylindncal stem portion (17) which closely sunounds the
- a jet mounting portion which includes a jet (20A) which overlies a jet (20B) in the upper end of the inlet (12); and (c) a collar portion (21 ) which comprises a frusto conical plate (22) surrounding the jet mounting po ⁇ ion (19) and
- the inner generally cylindrical surface (21A) of the collar portion (21) immediately sunounding the jet comprises a frusto-conical surface of the apex of which is below the collar and is at an angle of about 8° to the axis.
- the jet (20A) and jet (20B) combine to provide a gas/liquid mixing jet (20).
- the collar (32) communicates via pathways (33, 34) with an ambient air inlet (36) mounted on the side of the outer housing (27).
- the ambient air inlet (36) is closed by a one way valve (37) in the form of a flexible diaphragm (38) of plastic, neoprene, or rubber mounted centrally at (39) and which engages with a rim (41) sunounding the ambient air inlet (36).
- the ambient air inlet (36) includes a circular opening (42) defined by the rim (41) and an adjustable air controller (43) is provided
- the adjustable air controller (43) comprises a plate like member (44) mounted to slide vertically with respect to the housing (27) and includes an aperture (46) which, as the plate (44) slides, may selectively align with the circular opening (42).
- Figure 2 shows the general arrangement of the plate (44), in a first position in which the air inlet (36) is closed and
- Figure 3 shows the plate (44) in a second position in which the air inlet (36) is open.
- Figures 4 shows the nebulizer with the plate (44) removed thereby showing more clearly the circular opening (42).
- each side of the opening (42) there is moulded into the outer housing (27) a pair of vertically extending edges (47, 48) which each include a respective ratchet track (51 , 52) which are illustrated in more detail in Figure 5.
- the plate (44) Spaced from and aligned into the conesponding vertically extending edges (47, 48), the plate (44) has ve ⁇ ically extending faces (53, 54) illustrated in Figure 6.
- Each face (53.54) includes a respective upper and lower tooth (56, 57) for engaging with the respective adjacent ratchet track (51 , 52).
- inlet tube (12) is connected by means of a flexible plastic pipe to a suitable pressurised supply of air or oxygen and the outlet (28) is connected, usually by tubes, to a patient.
- the plate (44) is slid up or down so that the aperture (46) coincides with the circular opening (42) to a desired extent and is held in the desired position by engagement of the teeth (56,57) with their respective ratchet tracks (51 ,52).
- the liquid medication passes from top reservoir (14) up the capillary path (18) and as the pressurised air or oxygen passes through the jet (20B), mixes with the liquid passing
- air is drawn into the ambient air inlet (36) via the one way valve (37), through the pathways (33,34) to join and mix with the nebulized stream assisting in the breaking up of the gas liquid stream into finer droplets and in increasing the aerosol output being delivered through the outlet (28).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nozzles (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96943222A EP0959925A1 (fr) | 1995-12-20 | 1996-12-20 | Nebuliseur |
AU12017/97A AU1201797A (en) | 1995-12-20 | 1996-12-20 | Nebulizer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9526100.4 | 1995-12-20 | ||
GB9526100A GB9526100D0 (en) | 1995-12-20 | 1995-12-20 | Nebulizer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997022376A1 true WO1997022376A1 (fr) | 1997-06-26 |
Family
ID=10785782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/003201 WO1997022376A1 (fr) | 1995-12-20 | 1996-12-20 | Nebuliseur |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0959925A1 (fr) |
AU (1) | AU1201797A (fr) |
GB (1) | GB9526100D0 (fr) |
WO (1) | WO1997022376A1 (fr) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002417A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations |
WO2005097175A2 (fr) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Corps mimetiques glp-1 humains, compositions, procedes et utilisations |
WO2008021237A1 (fr) | 2006-08-10 | 2008-02-21 | Arubor Corporation | Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire |
EP2090657A2 (fr) | 2000-08-07 | 2009-08-19 | Centocor Ortho Biotech Inc. | Anticorps anti-IL-12, compositions, procédés et utilisations |
EP2123675A2 (fr) | 2003-09-30 | 2009-11-25 | Centocor Ortho Biotech Inc. | Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations |
EP2159230A1 (fr) | 2000-08-07 | 2010-03-03 | Centocor Ortho Biotech Inc. | Anticorps anti-TNF, compositions, procédés et utilisations |
WO2010051274A2 (fr) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations |
US7718176B2 (en) | 2004-09-03 | 2010-05-18 | Cna Development Llc | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
WO2010093627A2 (fr) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
EP2253646A1 (fr) | 2000-08-07 | 2010-11-24 | Centocor Ortho Biotech Inc. | Anticorps anti intégrines doubles et compositions et conjugés les contenant |
EP2308888A1 (fr) | 2001-11-14 | 2011-04-13 | Centocor Ortho Biotech Inc. | Anticorps anti-IL-6, compositions, méthodes et utilisations associées |
WO2011100403A1 (fr) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Anticorps anti-cd20 et utilisations de ceux-ci |
EP2452694A1 (fr) | 2005-06-30 | 2012-05-16 | Janssen Biotech, Inc. | Anticorps anti-IL-23, compositions, procédés et utilisations |
EP2548577A1 (fr) | 2005-12-29 | 2013-01-23 | Janssen Biotech, Inc. | Anticorps humains anti-IL-23, compositions, procédés et utilisations |
WO2014106459A2 (fr) | 2013-01-07 | 2014-07-10 | Superlab Far East Limited | Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée |
WO2014144763A2 (fr) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | Anticorps anti-gd2 à haute affinité |
EP2842968A1 (fr) | 2005-04-29 | 2015-03-04 | Janssen Biotech, Inc. | Anticorps anti-IL-6, compositions, procédés et utilisations |
KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-il-12/il-23 항체 |
WO2018014039A1 (fr) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation |
WO2018014038A1 (fr) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Récepteurs antigéniques chimériques et leurs procédés d'utilisation |
EP3323830A1 (fr) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anticorps anti-gd2 |
WO2018140026A1 (fr) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Molécules bispécifiques de liaison à her2 et cd3 |
WO2019126574A1 (fr) | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions de vcar et méthodes d'utilisation |
WO2019215701A1 (fr) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Méthodes de traitement de la dépression à l'aide d'anticorps il-23 |
WO2020148651A1 (fr) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile |
WO2020152544A1 (fr) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique |
WO2020183269A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf |
WO2020183271A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de production de compositions d'anticorps anti-tnf |
WO2020183270A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de production de compositions d'anticorps anti-tnf |
WO2020245676A1 (fr) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique |
WO2020245677A1 (fr) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active |
WO2021028752A1 (fr) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anticorps anti-tfn pour le traitement du diabète de type i |
US11014982B2 (en) | 2017-02-07 | 2021-05-25 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
US11041020B2 (en) | 2017-01-30 | 2021-06-22 | Janssen Biotech, Inc. | Methods for the treatment of active Psoriatic Arthritis |
WO2021211628A1 (fr) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions et méthodes destinées à être utilisées dans le traitement du cancer |
WO2021214587A1 (fr) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Agent anti-tnf alpha pour traiter des infections virales |
WO2021214588A1 (fr) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Agent anti-tnf alpha pour traiter des infections à coronavirus |
WO2022026943A2 (fr) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales |
WO2023279115A1 (fr) | 2021-07-02 | 2023-01-05 | Henry Ford Health System | COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2 |
WO2023281463A1 (fr) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Procédés de fabrication pour produire des compositions d'anticorps anti-tnf |
WO2023281462A1 (fr) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Procédés de fabrication pour produire des compositions d'anticorps anti-tnf |
EP4190817A1 (fr) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anticorps anti-muc16 et leurs utilisations |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986001731A1 (fr) * | 1984-09-18 | 1986-03-27 | Vortran Corporation | Vaporisateur servant a divers usages |
US4819629A (en) * | 1986-10-28 | 1989-04-11 | Siemens Aktiengesellschaft | Method and apparatus for delivering aerosol to the airways and/or lungs of a patient |
US5054477A (en) * | 1986-09-22 | 1991-10-08 | Omron Tateisi Electronics Co. | Nebulizer |
US5301662A (en) * | 1991-09-25 | 1994-04-12 | Cimco, Inc. | Nebulizer with high oxygen content and high total flow rate |
-
1995
- 1995-12-20 GB GB9526100A patent/GB9526100D0/en active Pending
-
1996
- 1996-12-20 EP EP96943222A patent/EP0959925A1/fr not_active Withdrawn
- 1996-12-20 AU AU12017/97A patent/AU1201797A/en not_active Abandoned
- 1996-12-20 WO PCT/GB1996/003201 patent/WO1997022376A1/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986001731A1 (fr) * | 1984-09-18 | 1986-03-27 | Vortran Corporation | Vaporisateur servant a divers usages |
US5054477A (en) * | 1986-09-22 | 1991-10-08 | Omron Tateisi Electronics Co. | Nebulizer |
US4819629A (en) * | 1986-10-28 | 1989-04-11 | Siemens Aktiengesellschaft | Method and apparatus for delivering aerosol to the airways and/or lungs of a patient |
US5301662A (en) * | 1991-09-25 | 1994-04-12 | Cimco, Inc. | Nebulizer with high oxygen content and high total flow rate |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3118318A1 (fr) | 2000-08-07 | 2017-01-18 | Janssen Biotech, Inc. | Anticorps anti-tnf, compositions, procédés et utilisations |
EP3597752A1 (fr) | 2000-08-07 | 2020-01-22 | Janssen Biotech, Inc. | Anticorps anti-il-12, compositions, procédés et utilisations |
EP2330129A2 (fr) | 2000-08-07 | 2011-06-08 | Centocor Ortho Biotech Inc. | Anticorps anti-TNF, compositions, procédés et utilisations |
EP2090657A2 (fr) | 2000-08-07 | 2009-08-19 | Centocor Ortho Biotech Inc. | Anticorps anti-IL-12, compositions, procédés et utilisations |
EP2159230A1 (fr) | 2000-08-07 | 2010-03-03 | Centocor Ortho Biotech Inc. | Anticorps anti-TNF, compositions, procédés et utilisations |
EP2305817A2 (fr) | 2000-08-07 | 2011-04-06 | Centocor Ortho Biotech Inc. | Anticorps anti-IL-12, compositions, procédés et utilisations |
EP2253646A1 (fr) | 2000-08-07 | 2010-11-24 | Centocor Ortho Biotech Inc. | Anticorps anti intégrines doubles et compositions et conjugés les contenant |
EP2308888A1 (fr) | 2001-11-14 | 2011-04-13 | Centocor Ortho Biotech Inc. | Anticorps anti-IL-6, compositions, méthodes et utilisations associées |
WO2004002417A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations |
EP2123675A2 (fr) | 2003-09-30 | 2009-11-25 | Centocor Ortho Biotech Inc. | Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations |
WO2005097175A2 (fr) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Corps mimetiques glp-1 humains, compositions, procedes et utilisations |
US7718176B2 (en) | 2004-09-03 | 2010-05-18 | Cna Development Llc | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
EP2842968A1 (fr) | 2005-04-29 | 2015-03-04 | Janssen Biotech, Inc. | Anticorps anti-IL-6, compositions, procédés et utilisations |
EP3501537A1 (fr) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anticorps anti-il23, compositions, procédés et utilisations |
EP2452694A1 (fr) | 2005-06-30 | 2012-05-16 | Janssen Biotech, Inc. | Anticorps anti-IL-23, compositions, procédés et utilisations |
EP3760230A1 (fr) | 2005-12-29 | 2021-01-06 | Janssen Biotech, Inc. | Anticorps humains anti-il-23, compositions, procédés et utilisations |
EP3219328A1 (fr) | 2005-12-29 | 2017-09-20 | Janssen Biotech, Inc. | Compositions, procédés et utilisations d'anticorps humains anti-il-23 |
EP2548577A1 (fr) | 2005-12-29 | 2013-01-23 | Janssen Biotech, Inc. | Anticorps humains anti-IL-23, compositions, procédés et utilisations |
US11718853B2 (en) | 2006-08-10 | 2023-08-08 | Onspira Therapeutics, Inc. | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
EP3669878A1 (fr) | 2006-08-10 | 2020-06-24 | Roy C. Levitt | Thérapie localisée des troubles inflammatoires des voies respiratoires inférieures avec des inhibiteurs de cytokines inflammatoires |
WO2008021237A1 (fr) | 2006-08-10 | 2008-02-21 | Arubor Corporation | Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-il-12/il-23 항체 |
EP3128048A1 (fr) | 2008-10-31 | 2017-02-08 | Janssen Biotech, Inc. | Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations |
WO2010051274A2 (fr) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations |
WO2010093627A2 (fr) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations |
WO2011100403A1 (fr) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Anticorps anti-cd20 et utilisations de ceux-ci |
EP3323830A1 (fr) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anticorps anti-gd2 |
EP4269563A2 (fr) | 2010-06-19 | 2023-11-01 | Memorial Sloan-Kettering Cancer Center | Anticorps anti-gd2 |
WO2014106459A2 (fr) | 2013-01-07 | 2014-07-10 | Superlab Far East Limited | Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée |
EP3895725A2 (fr) | 2013-01-07 | 2021-10-20 | Superlab Far East Limited | Procédé de traitement de tumeurs au moyen d'interféron recombinant à configuration spatiale modifiée |
WO2014144763A2 (fr) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | Anticorps anti-gd2 à haute affinité |
EP4190817A1 (fr) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anticorps anti-muc16 et leurs utilisations |
WO2018014038A1 (fr) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Récepteurs antigéniques chimériques et leurs procédés d'utilisation |
WO2018014039A1 (fr) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation |
WO2018140026A1 (fr) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Molécules bispécifiques de liaison à her2 et cd3 |
US11041020B2 (en) | 2017-01-30 | 2021-06-22 | Janssen Biotech, Inc. | Methods for the treatment of active Psoriatic Arthritis |
US11014982B2 (en) | 2017-02-07 | 2021-05-25 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2019126574A1 (fr) | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions de vcar et méthodes d'utilisation |
WO2019215701A1 (fr) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Méthodes de traitement de la dépression à l'aide d'anticorps il-23 |
WO2020148651A1 (fr) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile |
WO2020152544A1 (fr) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique |
WO2020183271A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de production de compositions d'anticorps anti-tnf |
WO2020183270A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de production de compositions d'anticorps anti-tnf |
WO2020183269A1 (fr) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
WO2020245677A1 (fr) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active |
WO2020245676A1 (fr) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique |
WO2021028752A1 (fr) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anticorps anti-tfn pour le traitement du diabète de type i |
WO2021211628A1 (fr) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions et méthodes destinées à être utilisées dans le traitement du cancer |
WO2021214587A1 (fr) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Agent anti-tnf alpha pour traiter des infections virales |
WO2021214588A1 (fr) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Agent anti-tnf alpha pour traiter des infections à coronavirus |
WO2022026943A2 (fr) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales |
WO2023279115A1 (fr) | 2021-07-02 | 2023-01-05 | Henry Ford Health System | COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2 |
WO2023281462A1 (fr) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Procédés de fabrication pour produire des compositions d'anticorps anti-tnf |
WO2023281463A1 (fr) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Procédés de fabrication pour produire des compositions d'anticorps anti-tnf |
Also Published As
Publication number | Publication date |
---|---|
GB9526100D0 (en) | 1996-02-21 |
EP0959925A1 (fr) | 1999-12-01 |
AU1201797A (en) | 1997-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0959925A1 (fr) | Nebuliseur | |
US7726306B2 (en) | Intra-oral nebulizer with rainfall chamber | |
EP0880373B1 (fr) | Dispositif de nebulisation | |
AU712312B2 (en) | Breathing circuit apparatus for a nebulizer | |
US9907918B2 (en) | Nebulizer apparatus and method | |
US7712466B2 (en) | Intra-oral nebulizer | |
EP0653946B1 (fr) | Nebuliseur a faible debit | |
CA1130160A (fr) | Atomiseur a debit reglable | |
US7493898B2 (en) | Inhalation apparatus | |
DE19726110A1 (de) | Ultraschallvernebler für Beatmungssysteme | |
US8439030B2 (en) | Nebulizer device | |
AU2004202959B2 (en) | Nebulizer Apparatus and Method | |
AU771684B2 (en) | Nebulizer apparatus and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996943222 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97522603 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996943222 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996943222 Country of ref document: EP |